We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dysregulated Tyrosine Kinase Signaling in Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00277056
Recruitment Status : Completed
First Posted : January 13, 2006
Last Update Posted : January 7, 2010
Information provided by:

Study Description
Brief Summary:
Dysregulated Tyrosine Kinase Signaling in Leukemia

Condition or disease

Detailed Description:
Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying

Study Design

Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dysregulated Tyrosine Kinase Signaling in Leukemia
Study Start Date : May 2002
Primary Completion Date : October 2005
Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia
U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Biospecimen Retention:   Samples With DNA
blood bone marrow

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
people with leukemia

Inclusion Criteria:

  • Patients must have newly diagnosed or relapsed leukemia.
  • Patients must sign an informed consent.
  • Patients will not be excluded if they are receiving chemotherapy.
  • Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.
  • Patients must be => 18 years of age.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00277056

United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Principal Investigator: Ian Rabinowitz, MD University of New Mexico
More Information

Responsible Party: Ian Rabinowitz, MD, University of New Mexico CRTC
ClinicalTrials.gov Identifier: NCT00277056     History of Changes
Other Study ID Numbers: 1602C
First Posted: January 13, 2006    Key Record Dates
Last Update Posted: January 7, 2010
Last Verified: April 2008

Keywords provided by University of New Mexico:

Additional relevant MeSH terms:
Neoplasms by Histologic Type